1. Home
  2. SNGX vs GTBP Comparison

SNGX vs GTBP Comparison

Compare SNGX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.23

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.41

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
GTBP
Founded
1987
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
12.1M
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
SNGX
GTBP
Price
$1.23
$0.41
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
108.6K
798.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.39
52 Week High
$6.23
$3.73

Technical Indicators

Market Signals
Indicator
SNGX
GTBP
Relative Strength Index (RSI) 52.45 33.71
Support Level $1.19 $0.41
Resistance Level $1.22 $0.59
Average True Range (ATR) 0.06 0.04
MACD 0.02 0.00
Stochastic Oscillator 60.27 22.64

Price Performance

Historical Comparison
SNGX
GTBP

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: